Alpha 2.0
Login Register
» Articles » PMID: 39998600

Detection of Substantial Numbers of Latent Tuberculosis and Positive Hepatitis B Serology Results in Rheumatology Patients Preparing to Receive Intensified Immunosuppressive Therapy in a Low-prevalence Country: Why Screening Still Matters

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2025 Feb 25
PMID 39998600
Authors
Martin Feuchtenberger
Magdolna Szilvia Kovacs
Axel Nigg
Arne Schafer
Affiliations
Soon will be listed here.
Abstract

Introduction /objectives: International guidelines recommend screening for latent tuberculosis infection (LTBI) and chronic viral hepatitis infections before initiating intensified immunosuppressive therapy. We assessed the prevalence of positive screening tests for LTBI, hepatitis B virus (HBV), and hepatitis C virus (HCV) in patients screened at a large rheumatology outpatient center in Germany.

Method: This retrospective cohort study used electronic health records from adult rheumatology patients. The presence of LTBI was evaluated by chest X-rays, patient medical history/self-report, and QuantiFERON®-TB Gold Plus (QFT) interferon-gamma release assays. Antibodies to HBV core antigen (anti-HBc) and HCV were used to assess HBV and HCV, respectively. Statistically significant associations were evaluated by Fisher exact tests.

Results: Of 697 screened patients with a rheumatological condition (61.3% female, mean age 60.0 years), 132 (18.9%) patients were positive for LTBI (99 [14.2%]), anti-HBc (39 [5.6%]), or anti-HCV (3 [0.4%]). Nine patients had more than one positive result; different infections were not significantly associated. QFT detected the most LTBI cases (59.5%) followed by patient report/history (42.4%) and chest X-rays (17.2%). Although most patients (83.8%) were positive on only one test, associations among LTBI tests were statistically significant. Biologic disease-modifying antirheumatic drug (bDMARD) use was lower in patients with a positive LTBI screening result compared with all screened patients (73.7% vs 86.4%) and targeted synthetic DMARD (tsDMARD) use was higher (10.1% vs 5.9%).

Conclusions: Almost one-fifth of rheumatology patients preparing to initiate intensified immunosuppressive therapy have positive results on screening tests for LTBI or show evidence of exposure to HBV or HCV. These findings support the need for careful screening, even in "low-prevalence" countries.

References
1.
Novosad S, Winthrop K . Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis. 2014; 58(11):1587-98. DOI: 10.1093/cid/ciu104. View
2.
Gomez-Reino J, Carmona L, Rodriguez Valverde V, Martin Mola E, Montero M . Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48(8):2122-7. DOI: 10.1002/art.11137. View
3.
Ai J, Zhang S, Ruan Q, Yu Y, Zhang B, Liu Q . The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. J Rheumatol. 2015; 42(12):2229-37. DOI: 10.3899/jrheum.150057. View
4.
Lan J, Chen Y, Hsieh T, Chen Y, Hsieh C, Chen D . Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011; 70(10):1719-25. DOI: 10.1136/ard.2010.148783. View
5.
Lee Y, Bae S, Song G . Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013; 16(5):527-31. DOI: 10.1111/1756-185X.12154. View